Geode Capital Management’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-689,447
| Closed | -$23.8M | – | 4347 |
|
|
2020
Q3 | $23.8M | Buy |
689,447
+7,659
| +1% | +$163K | ﹤0.01% | 1403 |
|
|
2020
Q2 | $11.4M | Buy |
681,788
+24,131
| +4% | +$410K | ﹤0.01% | 1857 |
|
|
2020
Q1 | $9.48M | Buy |
657,657
+53,943
| +9% | +$1.38M | ﹤0.01% | 1758 |
|
|
2019
Q4 | $20.2M | Buy |
603,714
+43,869
| +8% | +$1.23M | ﹤0.01% | 1552 |
|
|
2019
Q3 | $11.7M | Buy |
559,845
+13,298
| +2% | +$271K | ﹤0.01% | 1832 |
|
|
2019
Q2 | $11.4M | Buy |
546,547
+52,537
| +11% | +$1.08M | ﹤0.01% | 1857 |
|
|
2019
Q1 | $11M | Buy |
494,010
+21,785
| +5% | +$513K | ﹤0.01% | 1830 |
|
|
2018
Q4 | $11.3M | Buy |
472,225
+28,694
| +6% | +$742K | ﹤0.01% | 1704 |
|
|
2018
Q3 | $12.1M | Buy |
443,531
+16,938
| +4% | +$479K | ﹤0.01% | 1781 |
|
|
2018
Q2 | $11.5M | Buy |
426,593
+48,450
| +13% | +$1.48M | ﹤0.01% | 1771 |
|
|
2018
Q1 | $12M | Buy |
378,143
+113,566
| +43% | +$4M | ﹤0.01% | 1633 |
|
|
2017
Q4 | $10M | Buy |
264,577
+16,804
| +7% | +$542K | ﹤0.01% | 1742 |
|
|
2017
Q3 | $6.14M | Buy |
247,773
+8,079
| +3% | +$174K | ﹤0.01% | 2072 |
|
|
2017
Q2 | $4.93M | Buy |
239,694
+32,484
| +16% | +$620K | ﹤0.01% | 2151 |
|
|
2017
Q1 | $4.5M | Buy |
207,210
+10,461
| +5% | +$215K | ﹤0.01% | 2181 |
|
|
2016
Q4 | $4.02M | Buy |
196,749
+6,028
| +3% | +$123K | ﹤0.01% | 2199 |
|
|
2016
Q3 | $2.86M | Buy |
190,721
+78,615
| +70% | +$1.06M | ﹤0.01% | 2327 |
|
|
2016
Q2 | $1.21M | Buy |
112,106
+19,183
| +21% | +$261K | ﹤0.01% | 2797 |
|
|
2016
Q1 | $1.26K | Buy |
92,923
+20,452
| +28% | +$319K | ﹤0.01% | 2759 |
|
|
2015
Q4 | $1.34M | Buy |
72,471
+5,725
| +9% | +$106K | ﹤0.01% | 2749 |
|
|
2015
Q3 | $1.69M | Buy |
+66,746
| New | +$1.56M | ﹤0.01% | 2552 |
|
Geode Capital Management's AIMT Position: Q4 2020 in Review
Geode Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 689,447 shares — an estimated $23.8M sold.
Geode Capital Management first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $23.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Geode Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Geode Capital Management sold 689,447 Aimmune Therapeutics shares in Q4 2020, an estimated $23.8M.
- Geode Capital Management first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Geode Capital Management's Aimmune Therapeutics position peaked at $23.8M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Geode Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.